⌘K
Loading ticker…
As of 2026-08-24, CRISPR Therapeutics AG (CRSP) has a 3-month relative strength percentile of 72 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 52. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.2%, relative volume 0.71×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
CRSP is held by 14 ETFs as of May 2026. Top owner: VTWO at 0.15% weight, $26M notional. Top 3 carry $36M.
Held by 27 ETFs · $544M across latest filings · largest weight 8.91% (ARKG).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.15% | $26M | −0.02 pp |
| AVSC | 0.21% | $6M | −0.03 pp |
| VTWV | 0.32% | $4M | −0.03 pp |
| GNOM | 3.85% | $2M | +0.36 pp |
| ESML | 0.07% | $2M | — |
| ESGV | 0.01% | $1M | — |
| AVUSAvantis U.S. Equity ETF | 0.01% | $877K | — |
| VTHRVanguard Russell 3000 ETF | 0.01% | $437K | — |
| WSML | 0.05% | $308K | new |
| IBBQ | 0.43% | $289K | — |
Showing 10 of 14 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CRSP Jan avg: 6.75% median: 3.11% win: 75% σ: 13.21% n: 4 2022-04-12 → 2026-07-31 | CRSP Feb avg: 14.11% median: 12.99% win: 75% σ: 16.36% n: 4 2022-04-12 → 2026-07-31 | CRSP Mar avg: -17.70% median: -19.98% win: 0% σ: 6.42% n: 4 2022-04-12 → 2026-07-31 | CRSP Apr avg: -1.93% median: 8.20% win: 60% σ: 17.33% n: 5 2022-04-12 → 2026-07-31 | CRSP May avg: 10.09% median: 7.34% win: 80% σ: 14.37% n: 5 2022-04-12 → 2026-07-31 | CRSP Jun avg: 4.79% median: 0.50% win: 60% σ: 17.51% n: 5 2022-04-12 → 2026-07-31 | CRSP Jul avg: 7.05% median: 6.07% win: 80% σ: 13.51% n: 5 2022-04-12 → 2026-07-31 | CRSP Aug avg: -12.64% median: -12.99% win: 0% σ: 3.63% n: 4 2022-04-12 → 2026-07-31 (current) | CRSP Sep avg: 3.66% median: -0.58% win: 50% σ: 14.85% n: 4 2022-04-12 → 2026-07-31 | CRSP Oct avg: -9.16% median: -7.75% win: 0% σ: 9.42% n: 4 2022-04-12 → 2026-07-31 | CRSP Nov avg: 17.49% median: 7.49% win: 75% σ: 37.75% n: 4 2022-04-12 → 2026-07-31 | CRSP Dec avg: -14.25% median: -14.64% win: 0% σ: 11.95% n: 4 2022-04-12 → 2026-07-31 |